Showing results (81-90 of 175) with videos related to

Sort By:
Pageof 18
Cancer|May 2, 2022
Defining disease modification in myelofibrosis in the era of targeted therapyNaveen Pemmaraju, Srdan Verstovsek, Ruben Mesa, et al.
Leukemia & Lymphoma|June 1, 2016
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasmsTariq I Mughal, Omar Abdel-Wahab, Raajit Rampal, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Annals of Hematology|August 15, 2024
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosisGhaith Abu-Zeinah, Albert Qin, Harinder Gill, et al.
European Journal of Haematology|January 29, 2008
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosisAyalew Tefferi, Naseema Gangat, Alexandra P Wolanskyj, et al.
American Journal of Hematology|June 28, 2014
How common are myeloproliferative neoplasms? A systematic review and meta-analysisGlen J Titmarsh, Andrew S Duncombe, Mary Frances McMullin, et al.
Blood|December 24, 2023
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEALAaron T Gerds, Ruben Mesa, John M Burke, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2025
The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to ImplementationThomas G Knight, Caitlin Hensel, Kris Blackley, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
British Journal of Haematology|October 4, 2005
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemiaAyalew Tefferi, Shireen Sirhan, Terra L Lasho, et al.
Pageof 18